scholarly journals CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge

mSphere ◽  
2021 ◽  
Vol 6 (2) ◽  
Author(s):  
Yan Yan ◽  
Kai Hu ◽  
Ming Fu ◽  
Xu Deng ◽  
Sukun Luo ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Immune Responses ◽  
Glycoprotein D ◽  
Systemic Immunity ◽  
Virus Challenge ◽  
Mucosal Infection ◽  
Chemokine Ccl19 ◽  
Simplex Virus ◽  
Herpes Simplex Virus 2

An effective HSV-2 vaccine should induce antigen (Ag)-specific immune responses against viral mucosal infection. This study reveals that chemokine CCL19 or CCL28 enhanced HSV-2 glycoprotein D ectodomain (gD-306aa)-induced immune responses against vaginal virus challenge.

Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2

Vaccine ◽  
1993 ◽  
Vol 11 (6) ◽  
pp. 629-636 ◽  
Author(s):  
Masatoshi Hazama ◽  
Aki Mayumi-Aono ◽  
Naoki Asakawa ◽  
Shun'ichi Kuroda ◽  
Shuji Hinuma ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Immune Responses ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Interleukin 2 ◽  
Biologically Active ◽  
Glycoprotein D ◽  
Simplex Virus

scholarly journals Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.

1985 ◽  
Vol 56 (3) ◽  
pp. 1014-1017 ◽  
Author(s):  
R J Eisenberg ◽  
C P Cerini ◽  
C J Heilman ◽  
A D Joseph ◽  
B Dietzschold ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Glycoprotein D ◽  
Virus Challenge ◽  
Simplex Virus

scholarly journals Antiviral Activity of a Single-Domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2

2014 ◽  
Vol 59 (1) ◽  
pp. 527-535 ◽  
Author(s):  
Eileen M. Geoghegan ◽  
Hong Zhang ◽  
Prashant J. Desai ◽  
Arya Biragyn ◽  
Richard B. Markham
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Single Domain ◽  
Surface Glycoprotein ◽  
Glycoprotein D ◽  
Single Domain Antibody ◽  
Domain Antibody ◽  
Infected Cells ◽  
Simplex Virus ◽  
Herpes Simplex Virus 2

ABSTRACTDespite years of research dedicated to preventing the sexual transmission of herpes simplex virus 2 (HSV-2), there is still no protective vaccine or microbicide against one of the most common sexually transmitted infections in the world. Using a phage display library constructed from a llama immunized with recombinant HSV-2 glycoprotein D, we identified a single-domain antibody VHH, R33, which binds to the viral surface glycoprotein D. Although R33 does not demonstrate any HSV-2 neutralization activityin vitro, when expressed with the cytotoxic domain of exotoxin A, the resulting immunotoxin (R33ExoA) specifically and potently kills HSV-2-infected cells, with a 50% neutralizing dilution (IC50) of 6.7 nM. We propose that R33ExoA could be used clinically to prevent transmission of HSV-2 through killing of virus-producing epithelial cells during virus reactivation. R33 could also potentially be used to deliver other cytotoxic effectors to HSV-2-infected cells.

An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model

2017 ◽  
Vol 30 (3) ◽  
pp. 178-195 ◽  
Author(s):  
Kenneth C. Bagley ◽  
Jennifer A. Schwartz ◽  
Hanne Andersen ◽  
John H. Eldridge ◽  
Rong Xu ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Dna Vaccine ◽  
Subunit Vaccine ◽  
Interleukin 12 ◽  
High Dose ◽  
Glycoprotein D ◽  
Simplex Virus ◽  
Herpes Simplex Virus 2 ◽  
D Subunit
Sign in / Sign up

Export Citation Format

Share Document